IpraBio is your go-to source for innovative cell culture-based products, technologies, and related services.
IpraBio was established to market the strategic technologies designed by our parent company Ipratech to enhance the productivity and reduce the running costs of upstream cell culture processes.
IpraBio works with APIcells, a partnership that began with our first shared innovative technology brought to market: CYTOSYS, which is now widely used in the development and manufacturing facilities of biotech and pharmaceutical companies throughout Europe.
IpraBio is a source of expertise and process solutions for mAbs and recombinant proteins based on our mutual proprietary know-how to increase productivity with lower running costs and faster production time. Our technical skills combined with our extensive experience in cell culture offer you a unique solution to improve the reliability and the quality of your biological production.
The initial focus and success of IpraBio & APIcells has been on upstream design of any cell culture process based on fed-batch to perfusion with proven successes using typical cell lines, and in fermentation by adapting perfusion to a yeast-growing process.
Our expanding strategy for bioprocessing also benefits from the use of IpraBio’s proprietary model for perfusion control with CYTOSYS coupled to a perfusion device customized in-house or at our customer’s site for application to any cell culture process.
IpraBio brings you the opportunity to use our proprietary technologies for better productivity, faster results, and lower running costs. The company also promotes other technologies related to upstream processes in fermentation and cell culture.